Aclarion announced key milestone with their second payer coverage of Nociscan

Aclarion announced an additional key milestone with their second payer coverage of Nociscan by Aviva in London, UK in conjunction with The London Clinic. “This second payer coverage decision builds the momentum we expect to see in markets once one payer recognizes the advantages of paying for Nociscan,” said Brent Ness, CEO of Aclarion. “When you look at other diagnostic companies that market imaging combined with AI decision support solutions, you tend to see steady product adoption and value creation once payer coverage decisions are secured. HeartFlow in the cardiology space is a perfect example. Similar to Aclarion, they received their first payer coverage decision in the UK and were able to parlay that into a steady march towards standard of care and tremendous value creation for investors. I was a member of the early commercial development team at HeartFlow and intend to apply the same successful formula to Aclarion where we are addressing the larger market of low back pain. We welcome the second vote of confidence and key validation from UK payers and look forward to more.”